Jim Cramer Warns that Pfizer “Shareholder Base is Getting Very Restive”

Pfizer Inc. (NYSE:PFE) is one of the stocks in Jim Cramer’s game plan for this week. Cramer mentioned the company during the episode and said:

“There’s another one, that I’m not so sure of, reporting at the same time, though, Pfizer. We need to see some really dramatic results here from the clinical trials like the ones that Pfizer picked up when they bought the Seagen at the end of 2023. It’s enough time to see more than we’ve seen already, I gotta tell you that. And they better hurry up because the shareholder base is getting very restive, and who knows what the president has… against this industry.”

Pfizer (NYSE:PFE) develops and sells biopharmaceutical products, including vaccines, treatments for infectious diseases, oncology therapies, and biosimilars. When a caller asked for advice on the stock during the July 23 episode, he replied:

“I can’t ask you to do that because we are still on the verge of finding out what the Seagen acquisition does. Let’s give Dr. Bourla two more quarters, two more quarters, and then… we’re going to fish or cut bait, okay? Not yet. Two more quarters.”

While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.